^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH wild-type

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
Entrez ID:
Related biomarkers:
1d
Beyond Parkinsonism: 18F-FDOPA Brain PET/MRI for Detection of High-grade Glioma. (PubMed, Clin Nucl Med)
This unexpected finding prompted contrast-enhanced MRI brain, which identified a peripherally enhancing splenium lesion concerning for neoplasm. Stereotactic biopsy confirmed GFAP-positive, diffuse high-grade glioblastoma, IDH-wildtype, WHO Grade 4, highlighting the role of FDOPA PET in the assessment of primary brain tumors.
Journal
|
GFAP (Glial Fibrillary Acidic Protein)
|
IDH wild-type
2d
Mechanisms associated with temozolomide resistance in U87MG cell line: in silico and in vitro approaches. (PubMed, J Toxicol Environ Health A)
These findings indicated that DMC functions as an effective chemosensitizer, elevating TMZ efficacy. Combining DMC with DNA repair inhibitors may represent a promising therapeutic strategy to overcome resistance and improve IDH-wildtype grade diffuse glioma treatment outcomes.
Preclinical • Journal • PARP Biomarker
|
MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • PCNA (Proliferating cell nuclear antigen) • HSPA1A (Heat Shock Protein Family A (Hsp70) Member 1A)
|
IDH wild-type
|
temozolomide
4d
Anti-GD2 ADC M3554 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=52, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Mar 2028 --> Apr 2027 | Trial primary completion date: Mar 2027 --> Oct 2026
Trial completion date • Trial primary completion date • First-in-human
|
IDH wild-type
4d
Differential Expression of PIWI-interacting RNAs in Glioblastoma Stem Cells Affects Their Biological Features: Implications for Tumor Progression and Patient Survival. (PubMed, Lab Invest)
These molecules were further used for the establishment of piRNA signature predicting survival of GBM patients. Our results, not only, confirm the important role of piR-9491 in GSCs, but also indicate potentially significant role of piRNAs in the biology of GBM.
Journal
|
SOX2
|
IDH wild-type
5d
New P1 trial
|
EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
EGFR expression • IDH wild-type
6d
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Jan 2026
Enrollment closed • Trial primary completion date
|
IDH wild-type
|
temozolomide
6d
New P2 trial
|
IDH wild-type
|
temozolomide
7d
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells. (PubMed, Nat Chem Biol)
Interestingly, C269 autopalmitoylation occurs within a hydrophobic pocket, targeted by a clinical IDH1-mutant inhibitor (LY3410738). Our study reveals that autopalmitoylation, conferred by the IDH1R132H mutation, links fatty acid metabolism to the regulation of IDH1 mutant activity and represents a druggable vulnerability in IDH1-mutant cancers.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH wild-type • IDH1 R132
|
LY3410738
7d
Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis (PubMed, Zh Vopr Neirokhir Im N N Burdenko)
Original method based on marker gene expression ratios does not replace standard diagnostic protocols, but may be an additional tool for optimized diagnostic process. This approach will be valuable to minimize errors and personalize therapeutic strategies. The last one is critical for prognosis.
Journal
|
SOX2
|
IDH wild-type
8d
Characteristics of auditory event-related potential and prediction of IDH1 mutation in patients with insular glioma. (PubMed, Quant Imaging Med Surg)
The IDH1-wt group showed higher amplitude of MMN evoked by novel stimulus at Fz and Cz and longer latency of the P300 component evoked by a deviant stimulus at Fz. The combination of AERP parameters yielded a more effective means to predict IDH1 mutation status in patients with insular glioma, which may provide guidance for the surgical intervention of this disease.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH wild-type
|
Akeega (abiraterone/niraparib)
8d
Immune Cell Infiltration in Primary and Recurrent Glioblastoma, IDH-Wild Type: Validation of an Immunohistochemistry-Based Scoring System for Research and Clinical Practice. (PubMed, APMIS)
Cox proportional-hazards analysis showed worse survival with higher CD8+ and CD45+ infiltration in primary GBM, and higher CD45+ and CD68+ infiltration in recurrent GBM. In conclusion, we propose a feasible, cost-efficient, and robust method to assess immune infiltration on FFPE material, enabling standardized comparison of inflammation, with applications for ongoing clinical trials.
Journal
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD68 (CD68 Molecule)
|
IDH wild-type
10d
Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression. (PubMed, Sci Rep)
Here, we evaluated the survival outcomes between temozolomide (TMZ)-only and TMZ + BEV treatments stratified based on the cyclooxygenase-2 (COX-2) expression, a rate-limiting enzyme involved in the cancer development. In contrast, these benefits were not found in patients with low COX-2 expression (PFS: 12 vs. 15 months, p = 0.875; OS: 24 vs. 26 months, p = 0.775). Altogether, this study suggests that patients with high, but not low, COX-2 expression demonstrate survival benefits from the addition of BEV in ndGBM.
Journal
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
IDH wild-type
|
Avastin (bevacizumab) • temozolomide